Bayer shares: buy or sell? Analysis by financial experts

Bayer shares: buy or sell? Analysis by financial experts

According to a report by www.4investors.de, the Bayer share has been showing a potential stabilization around 27.40/27.70 euros for days, with core support at 27.40/27.44 euros. There were no reliable buy signals from the charts, and it is to be expected that cuts or even a loss of dividends are imminent. This uncertainty continues to put pressure on the share price as the share was unable to escape the price cellar.

From a financial perspective, Bayer shares are not yet ready for a significant improvement in the situation. There were no buy signals recently, and the countermoves ended at 29.345 euros and this week at 28.66 euros. The stabilization above EUR 27.40 has not yet triggered any significant countermoves.

Bayer shares are currently trading at 28.105 euros on Tradegate on Friday morning. The first possible pullback levels are still between 29.74 euros and 30.22/30.31 euros, but were not in “danger” during the recovery movement. In terms of chart technology, there is an important hurdle at 36.09 euros. A breakout above this could provide further bullish momentum. However, a stable fall below the 27.40/27.70 euro area could be seen as a technical sell signal.

Bayer is a multinational company active in the areas of healthcare, crop science and consumer health. The company employs more than 100,000 people in over 120 countries and has a strong presence in Europe, North America and Asia.

Overall, Bayer shares appear to remain under pressure for the time being, especially in view of the unclear dividend situation and the technical chart conditions.

How www.4investors.de reported, the Bayer Annual General Meeting on April 26th is approaching, which will entail a decision on any dividend distributions.